Dr. Arnab Chakravarti Has Been Recognized Among the Top in His Industry by the Expert Network©

Columbus, OH, January 21, 2016 (Newswire.com) - ​​​​​Dr. Arnab Chakravarti, Chair & Professor, Department of Radiation Oncology, Ohio State University, has joined The Expert Network, an invitation only service for distinguished professionals. Dr. Chakravarti​​​​ has been chosen as a Distinguished Doctor™ based on peer reviews and ratings, numerous recognitions, and accomplishments achieved throughout his career.

Dr. Chakravarti​​​​​ outshines others in his field due to his extensive educational background, recognitions, and career longevity. He graduated from the University of Virginia School of Medicine before completing his residencies at the Massachusetts General Hospital through Harvard Medical School. He is certified by the American Board of Radiology with a subspecialty in radiation oncology.

"In three to five years, we hope to translate a lot of our findings from the bench to the bedside. We also hope to start new clinical trials on novel investigational agents and novel investigational approaches that will improve the lives of cancer patients, and one day perhaps lead to a cure."

Arnab Chakravarti, M.D., Chair & Professor, Department of Radiation Oncology, Ohio State University

With over 20 years dedicated to medicine, Dr. Chakravarti​​​ brings a wealth of knowledge to his industry, and in particular, to his area of expertise, radiation oncology. When asked about the most important part of cancer care, Dr. Chakravarti​​​​​ said:

"I think the important thing is to make people aware of current cancer treatment techniques and to give them hope that there are many types of cancers that are both curable and treatable. We want to make sure that every cancer patient gets the best possible care."

As a thought-leader in his field, Dr. Chakravarti is also dedicated to advancing the knowledge base of radiation oncology through cutting edge research. Currently, his research focuses primarily on investigating the molecular, genetic, and epigenetic mechanisms of treatment resistance in human tumors, and developing strategies to circumvent this resistance. His research team has broken ground by uncovering new ways to target tumors. He noted:

"In three to five years, we hope to translate a lot of our findings from the bench to the bedside. We also hope to start new clinical trials on novel investigational agents and novel investigational approaches that will improve the lives of cancer patients, and one day perhaps lead to a cure."

Chakravatri currently serves as Chair of the Radiation Therapy Oncology Group (RTOG)’s Brain Tumor Translational Research Group and Co-Chair of the clinical RTOG Brain Tumor Committee. Further, he is the United States delegate on the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Steering Committee. He is also a standing member of the NIH Cancer Biomarkers Study Section (CBSS) and serves on NIH P01 and Specialized Programs of Research Excellence (SPORE) review panels, respectively. For his accomplishments, Dr. Chakravarti has been recognized as a Fellow of the American College of Radiation Oncology.

For more information, visit ​​​​Dr. Chakravarti​​'s profile on the Expert Network here: http://expertnetwork.co/members/arnab-chakravarti,-md/201a79861dbf4504​

###

The Expert Network has written this news release with approval and/or contributions from ​​​​Dr. Arnab Chakravarti​. The Expert Network is an invitation-only reputation management service that is dedicated to helping professionals stand out, network, and gain a competitive edge. The Expert Network selects a limited number of professionals based on their individual recognitions and history of personal excellence.